{"id":389001,"date":"2024-12-24T00:00:00","date_gmt":"2024-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0018-2024-biopharma-small-cell-lung-cancer-disease-landscape-forecast-g7-2024\/"},"modified":"2026-04-18T11:18:59","modified_gmt":"2026-04-18T11:18:59","slug":"dlsfon0018-2024-biopharma-small-cell-lung-cancer-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0018-2024-biopharma-small-cell-lung-cancer-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Small-Cell Lung Cancer | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication: Genentech\u2019s Tecentriq in 2019 and AstraZeneca&#8217;s Imfinzi in 2020 for treatment of extensive-stage disease across the G7 markets. Despite approval of these drugs, a substantial unmet need remains for better therapeutic options, especially in the later lines of therapy. However, the modest late-phase pipeline for SCLC is set to boost the market\u2014namely, with Amgen\u2019s bispecific T-cell engager (BiTE) tarlatamab and Daiichi\u2019s antibody-drug conjugate (ADC) ifinatamab deruxtecan. Nevertheless, considerable commercial potential remains for targeted agents that treat the underserved relapsed\/refractory SCLC population.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What are interviewed experts\u2019 insights on the current treatment options for SCLC?<\/li>\n<li>How large are the drug-treatable SCLC populations, and how will drug-treatment rates change over time?<\/li>\n<li>How will key emerging therapies shape the SCLC market over the 10-year forecast period?<\/li>\n<li>What key factors are driving or constraining market growth?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389001","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389001\/revisions"}],"predecessor-version":[{"id":575849,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389001\/revisions\/575849"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}